Oncocyte Provides Positive Update on Clinical Trial Progress
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 30 2025
0mins
Should l Buy ?
Source: Newsfilter
Clinical Trial Progress: Oncocyte Corp. has received approval from a central institutional review board for its clinical trial aimed at launching an organ transplant rejection monitoring test kit, with participation from three of the top 10 U.S. transplant centers.
Regulatory Pathway and Market Potential: The company is preparing for its final Q-sub meeting with the FDA to obtain regulatory authorization, with expectations that local testing could generate significant revenue and improve community care in the $1 billion annual market for transplant rejection testing.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
